Antituberculosis drug-induced hepatotoxicity: A comparison between patients with and without human immunodeficiency virus seropositivity;Hepatotoxicidade induzida pelos tuberculostáticos: Comparação em pacientes com e sem soropositividade para o vírus da imunodeficiência humana

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 43, Issue 6, 2010, Pages 624-628

  Coca, Natalia Saldanha Magalhǎes ^a   Oliveira, Marcelo Silva ^b   Voieta, Izabela ^a   Antunes, Carlos Maurício de Figueiredo ^a   Lambertucci, José Roberto ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Technological Center Foundation of Minas Gerais   (Brazil)

Author keywords

Antiretroviral drugs; Antituberculosis drugs; Hepatitis; Hepatotoxicity; Human immunodeficiency virus; Tuberculosis

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ABDOMINAL PAIN; ADULT; AGED; ALCOHOL ABUSE; ARTICLE; BRAZIL; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; DECREASED APPETITE; DISEASE ASSOCIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MALE; NAUSEA; PREVALENCE; RISK FACTOR; SYMPTOM; TOXIC HEPATITIS; TUBERCULOSIS; VOMITING;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 78651084844     PISSN: 00378682     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0037-86822010000600004     Document Type: Article

References (41)

1. World Health Organization. Global tuberculosis control: a short update to the 2009 report. WHO Press; WHO/HTM/TB/2009.426.
2. Lambertucci JR, Rayes AA, Gerspacher-Lara R. Salmonella S. Mansoni association in patients with acquired immunodeficiency syndrome. Rev Inst Med Trop Sao Paulo 1998; 40:233-235.
3. Herzog H. History of tuberculosis. Respiration 1998; 65:5-15.
4. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999; 282:677-686.
5. Lambertucci JR, Rayes AA, Nunes F, Landazuri-Palacios JE, Nobre V. Fever of undetermined origin in patients with the acquired immunodeficiency syndrome in Brazil: report on 55 cases. Rev Inst Med Trop S Paulo 1999; 41:27-32.
6. Teixeira Jr AL, Nobre V, Lambertucci JR. Respiratory failure due to opportunistic diseases in AIDS. Rev Soc Bras Med Trop 2002; 35:411-412.
7. Nobre V, Braga E, Rayes A, Serufo JC, Godoy P, Nunes N, et al. Opportunistic infections in patients with AIDS admitted to an university hospital of the Southeast of Brazil. Rev Inst Med Trop Sao Paulo 2003; 45:69-74.
8. Aaron L, Saadoun D, Calatroni I, Launay O, Mémain N, Vincent V, et al. Tuberculosis in HIV-infected patients: a comprehensive review. Clin Microbiol Infect 2004;10:388-398.
9. Nunn P, Williams B, Floyd K, Dye C, Elzinga G, Raviglione M. Tuberculosis control in the era of HIV. Nat Rev Immunol 2005; 5:819-826.
10. Comitê Técnico-Científico de Assessoramento à Tuberculose e Comitê Assessor para Coinfecção HIV-Tuberculose.Guia de Vigilância Epidemiológica. Brasília: Ministério da Saúde; 2002. v.1.p.31-33.
11. Rodrigues MC, Viotti JB, Braga RF, Lourenço LF, Antunes CM, Lambertucci JR. HIV/HCV coinfection in Infectious Disease Units in Mozambique and Brazil: a comparative study. Rev Soc Bras Med Trop 2008; 41:518.
12. Pedral-Sampaio DB, Martins Netto E, Alcântara AP, Souza J, Moura L, Brites C, et al. Use of standard therapy for tuberculosis is associated with increased adverse reactions in patients with HIV. Braz J Infect Dis 1997;1:123-130.
13. Hoffmann CJ, Charalambous S, Thio CL, Martin DJ, Pemba L, Fielding KL, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS 2007; 21:1301-1308.
14. Askgaard DS, Wilcke T, Døssing M. Hepatotoxicity caused by the combined action of isoniazid and rifampicin. Thorax 1995; 50:213-214.
15. Breen RA, Miller RF, Gorsuch T, Smith CJ, Schwenk A, Holmes W, et al. Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax 2006; 61:791-794.
16. El-Sadr WM, Tsiouris SJ. HIV-associated tuberculosis: diagnostic and treatment challenges. Semin Respir Crit Care Med 2008; 29:525-531.
17. Saraceni V, King BS, Cavalcante SC, Golub JE, Lauria LM, Moulton LH, et al. Tuberculosis as primary cause of death among AIDS cases in Rio de Janeiro, Brazil. Int J Tuberc Lung Dis 2008; 12:769-772.
18. Perriëns JH, St Louis ME, Mukadi YB, Brown C, Prignot J, Pouthier F, et al. Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. N Engl J Med 1995; 332:779-784.
19. Yew W, Leung C. Antituberculosis drugs and hepatotoxicity. Med Bull 2007; 12:7-9.
20. American Thoracic Society/Centers for Disease Control and Prevention Infectious Diseases Society of America. Treatment of Tuberculosis. Am J Respir Crit Care Med 2003; 167:603-662.
21. Fernandez-Villar A, Sopena B, Fernandez-Villar J. The influence of risk factors on the severity of antibuterculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 2004; 8:1499-1505.
22. Lambertucci JR, Cota GF, Pinto-Silva RA, Serufo JC, Gerspacher-Lara R, Costa Drummond S, et al. Hepatosplenic schistosomiasis in field-based studies: a combined clinical and sonographic definition. Mem Inst Oswaldo Cruz 2001; 96 (suppl 1):147-150.
23. Centro Panamericano de Zoonosis. Manual de normas y procedimientos tecnicos para la bacteriologia de la tuberculosis: Parte I. La muestra, El examen microscopico. CEPANZO. Notas Tecnicas, no 26/Rev. 1. Buenos Aires: CEPANZO; 1988.
24. Smithwick RW. Laboratory manual acid-fast microscopy. Atlanta (GA): Public Health Service, Center for Disease Control, Bureau of Laboratories; 1976.
25. Union International Contra la Tuberculosis. Guia tecnico para recoleción, conservación y transporte de las muestras de esputo y examen por microscopia direct para la tuberculosis. Bol Un Int Tuberc 1978; 53 (supl 2):1-21.
26. Fundação Nacional de Saúde. Centro de Referência Professor Helio Fraga. Manual de Bacteriologia da Tuberculose. 2nd ed. Rio de Janeiro: Ministério da Saúde; 1994.
27. Siddiqi SH. BACTEC 460 TB system. Product and procedure manual, revision D. Sparks (MD): Becton Dickinson Diagnostic Systems; 1995.
28. Dupont WD. Statistical Modeling for Biomedical Researchers, 2nd ed. Cambridge: Cambridge University Press UK; 2009.
29. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006; 354:731-739.
30. Ministério da Saúde. Programa Nacional de Controle da Tuberculose. Brasília: Editora Ministério da Saúde; 2002.
31. Ministério da Saúde. Guia de Vigilância Epidemiológica da Tuberculose. Brasília: Ministério da Saúde; 2009.
32. Chaisson RE, Clermont HC, Holt EA, Cantave M, Johnson MP, Atkinson J, et al. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med 1996; 154:1034-1038.
33. Nathwani RA, Kaplowitz N. Drug hepatotoxicity. Clin Liver Dis 2006; 10:207-217.
34. Pessayre D, Bentata M, Degott C, Nouel O, Miguet JP, Rueff B, et al. Isoniazidrifampin fulminant hepatitis. A possible consequence of the enhancement of isoniazid hepatotoxicity by enzyme induction. Gastroenterology 1977; 72:284-289.
35. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174:935-952.
36. Schaberg T. The dark side of antituberculosis therapy: adverse events involving liver function. Eur Respir J 1995; 8:1247-1249.
37. Tostmann A, Boeree MJ, Harries AD, Sauvageot D, Banda HT, Zijlstra EE. Short communication: antituberculosis drug-induced hepatotoxicity is unexpectedly low in HIV-infected pulmonary tuberculosis patients in Malawi. Trop Med Int Health 2007; 12:852-855.
38. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 2008; 23:192-202.
39. Yew WW, Leung CC. Antituberculosis drugs and hepatotoxicity. Respirology 2006; 11:699-707.
40. Willner IR, Reuben A. Alcohol and the liver. Curr Opin Gastroenterol 2005; 21:323-330.
41. Oliva VM, Cezário GAG, Cocato RA, Marcondes-Machado J. Pulmonary tuberculosis: hematology, serum biochemistry and the relation with the disease duration. J Venom Anim Toxins Incl Trop Dis 2008; 14:71-81.